Global biotechnology tool company Life Technologies Corporation (LIFE - Snapshot Report) recently launched its auto imaging system EVOS FL along with an on-stage incubator. Currently, any lab can access this system. This system enables high-resolution longer live automatic cell imaging for fluorescence microscopy and time-lapse imaging on single integrated platform.
In spite of advanced features, Life Technologies claims this system to be easy to operate and cheaper than its substitute instruments in the market. Thus, with the commercialization, adoptability of this EVOS FL is going to be high in the market.
Life Technologies enjoys a strong position in the life sciences market. We are optimistic about the company’s focus on its diagnostics franchise, which holds potential. Given the continuous focus on portfolio expansion, we are confident about Life Technologies garnering higher revenues from genetic analysis going forward.
In Feb 2013, a dozen new products for the Ion Torrent platform were launched based on advancing clinical research across the world. These new products enabled Ion Torrent semiconductor sequencing technology to expand 1,000-fold in just two years and gain a 60% market share of benchtop sequencers. The company is also positive about its Ion AmpliSeq Exome Kit which delivers industry’s best exome sequencing performance, with higher exome coverage.
We also note Life Technologies’ efforts to expand its footprint in high-growth markets through partnerships, acquisitions and product innovation.
Following the disclosure of its acquisition by Thermo Fisher Scientific Inc. (TMO - Analyst Report), Life sharpened focus on its product platform. We believe that the buyout, which is expected to close in early 2014, will leverage Life’s attractive revenue profile.
Given Life’s expansive line of consumables for genomic, and molecular and cell biology, the takeover will complement Thermo Fisher’s market-leading portfolio of analytical technologies and specialty diagnostics.
However, Life Technologies carries a Zacks Rank #4 (Sell). Some better performing medical stocks include Tornier N.V. and Lannett Company, Inc. (LCI - Snapshot Report) with a Zacks Rank #1 (Strong Buy).